Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
NCT07388550
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
15
Enrollment
NIH
Sponsor class
Conditions
Post-Acute COVID-19 Syndrome
Interventions
DRUG:
Keytruda
Sponsor
National Institute of Neurological Disorders and Stroke (NINDS)